Wu et al 1 conducted an interesting study-level meta-analysis comparing the efficacy of PD-1 antibody plus chemotherapy with chemotherapy alone in patients with PD-L1–expressing esophageal squamous ...

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study ...